Osiris Therapeutics, Inc. (OSIR) ended last trading session with a change of -25.77 percent. It trades at an average volume of 122.22K shares versus 2.92M shares recorded at the end of last trading session. The share price of $3.86 is at a distance of 8.73 percent from its 52-week low and down -47.77 percent versus its peak. The company has a market cap of $132.99M and currently has 34.45M shares outstanding. The share price is currently -32.69 percent versus its SMA20, -28.98 percent versus its SMA50, and -25.77 percent versus its SMA200. The stock has a weekly performance of -33.1 percent and is -21.38 percent year-to-date as of the recent close.
On March 10, 2017 Osiris Therapeutics, Inc. (OSIR) announced that the Company received a letter from the NASDAQ Stock Market (“NASDAQ”) stating that trading of the Company’s common stock will be suspended at the opening of business on Tuesday, March 14, 2017. The letter also states that NASDAQ will file a Form 25 with the SEC to formally delist the Company’s securities from NASDAQ, to become effective ten days after filing.
Amicus Therapeutics, Inc. (FOLD) recently recorded -3.97 percent change and currently at $7.25 is 64.4 percent away from its 52-week low and down -26.25 percent versus its peak. It has a past 5-day performance of -5.72 percent and trades at an average volume of 3.74M shares. The stock has a 1-month performance of 18.27 percent and is 45.88 percent year-to-date as of the recent close. There were about 142.36M shares outstanding which made its market cap $1.03B. The share price is currently 8.52 percent versus its SMA20, 21.28 percent versus its SMA50, and 10.15 percent versus its SMA200.
On March 01, 2017 Amicus Therapeutics, Inc. (FOLD) announced financial results for the full year ended December 31, 2016. The Company also provided program updates and reiterated full-year 2017 financial guidance.
“Throughout 2016 we made significant progress with the international launch of our first commercial product Galafold and continued to advance and expand our robust pipeline of first- and/or best-in-class medicines for people living with devastating rare diseases,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. “During 2017 we are laser focused on five key strategic priorities to advance our vision to develop and deliver great medicines for patients and to create significant shareholder value: 1) advancing the international launch of Galafold for Fabry disease, 2) completing our regulatory submission for migalastat in Japan (J-NDA), 3) establishing our novel Pompe treatment paradigm ATB200/AT2221 as a highly differentiated therapy, 4) successfully completing our Phase 3 clinical study in patients with epidermolysis bullosa, and 5) maintaining our financial strength. With one commercial-stage medicine and two medicines in clinical development, as well as a biologics platform for future growth, we are building a leading global biotechnology company focused on delivering meaningful benefits for patients living with devastating rare diseases.”